Metablok is under clinical development by Arch Biopartners and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Metablok’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Metablok overview
Metablok is under development for the treatment of sepsis, cancer metastasis and for prevention of acute kidney injury in cardiac surgery patients caused by inflammation, acute respiratory distress syndrome, acute kidney injury (AKI), cardiomyopathy, acute liver injury, coagulopathy caused by inflammation in coronavirus disease 2019. The drug candidate acts by targeting dipeptidase-1. The therapeutic candidate is a peptide drug with the sequence NH3-LSALTPSPSWLKYKAL-COOH. It is administered through intravenous route.
Arch Biopartners overview
Arch Biopartners operates as a drug development company that provides drug candidates for treating various bacterial infections. The company develops AB569, a drug for the treatment of lung and urinary tract bacterial infections. It also develops MetaBlok, a drug for the treatment of sepsis, cancer metastasis and inflammation based diseases to solid surfaces to inhibit biofilm formation and reduce corrosion; and inflammation treatments for chronic kidney and bowel diseases caused by non-infectious inflammation. Arch Biopartners is headquartered in Toronto, Canada.
For a complete picture of Metablok’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
